{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:12:51Z","timestamp":1772748771038,"version":"3.50.1"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.seizure.2017.02.019","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T16:17:18Z","timestamp":1489853838000},"page":"81-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01"],"prefix":"10.1016","volume":"47","author":[{"given":"Lara","family":"Kay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann Philipp","family":"Z\u00f6llner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp S.","family":"Reif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl Martin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2017.02.019_bib0005","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2017.02.019_bib0010","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/17512433.2016.1156529","article-title":"Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus","volume":"9","author":"Strzelczyk","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.seizure.2017.02.019_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WNF.0b013e318271220b","article-title":"Eslicarbazepine Acetate in the Management of Refractory Bipolar Disorder","volume":"35","author":"Nath","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2017.02.019_bib0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/epi.12564","article-title":"Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions","volume":"55","author":"Amstutz","year":"2014","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117301139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131117301139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:49:00Z","timestamp":1761011340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131117301139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":4,"alternative-id":["S1059131117301139"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2017.02.019","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2017.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}